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Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of
these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid
degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with
high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic
approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome
are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross
correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can
be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have
been successfully treated with ERT.
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Together with glycerophospholipids and cholesterol, sphin-
golipids are building blocks of eukaryotic membranes. They are
characterized by the presence of a sphingoid base within the
hydrophobic part of the molecule. In sphingomyelin and the
glycosphingolipids, a phosphorylcholine or a carbohydrate
moiety are bound to the terminal hydroxyl group of ceramide
(N-acylsphingosine), respectively (Fig. 1) [1].
Glycosphingolipids display a high structural diversity and
can be classified into series, which are characteristic for a group
of evolutionary related organisms [1]. On cellular surfaces,
glycosphingolipids form characteristic patterns that are species-
and cell-type specific and change with cell growth, differentia-
tion, viral transformation, ontogenesis, and oncogenesis [2]. In
the plasma membrane, they are believed to segregate into pre-
existing microdomains [3,4], which are enriched in glycosyl-
phosphatidylinositol-anchored proteins, sphingomyelin, and
cholesterol. These so-called lipid rafts [5,6] might constitute
the physiological surroundings of many membrane proteins.
Glycosphingolipids are essential for development and
survival of multicellular organisms [7]; they play a role in cell
adhesion phenomena [8,9] and in the regulation of membrane
proteins. Thus, absence of ganglioside GM3 in vivo leads to
enhanced insulin receptor phosphorylation and increased insulin
sensitivity [10]. Correct sphingolipid processing is also vital for
the barrier function of the human skin [11], where ceramides of
the stratum corneum contribute to the water permeability barrier.
Skin ceramides occur in free form [12], or covalently linked to
proteins of the cornified envelope [13]. In addition to disorders
caused by alterations of sphingolipid metabolism, sphingolipids
are involved in a variety of diseases [14]. In infectious diseases,
sphingolipids serve, e.g., as pathogen receptors [15–17] and can
control pathogen infection and host defense [18]. In the immune
system, glycosphingolipids play a role as antigens (ABO-
System, Forssman), but can also stimulate the generation of
autoantibodies in postinfectious autoimmune diseases like
Guillain–Barré or Miller–Fisher Syndromes [19,20]. They are
ligands for CD1d-restricted natural killer T-cells (NKT-cells)[32]; for example, the highly immunogenic, non-human α-
galactosylphytoceramide activates a subset of NKT cells. This
glycosphingolipid from the marine sponge Agelas mauritianus
[21] has gained much interest as a potential drug in the treatment
of cancer and autoimmune diseases [22,23]. An endogenous
sphingolipid ligand for CD1d and important for the maturation
of NKT-cells appears to be isoglobotriaosylceramide. This was
demonstrated by a deficiency of invariant NKT-cells in β-
hexosaminidase B-deficient mice, the animal model of Sandhoff
diseases, which cannot convert isoglobotetraosylceramide into
isoglobotriaosylceramide [24].
1.1. Less precisely defined is the role of sphingolipids in cancer
[25]
Intermediates of sphingolipid metabolism appear to be
involved in the transduction of extracellular signals into the
interior of cells. Ceramide can be released from sphingomyelin or
by de-novo synthesis in response to substances like vitamin D3,
tumor necrosis factorα, γ-interferon, or interleukin 1. Inmost cell
types, ceramide mediates antimitogenic responses such as cell
differentiation, cell cycle arrest, cell senescence or apoptosis [26].
Also other intermediates of sphingolipid metabolism such as
sphingosine, sphingosylphosphorylcholine [27], sphingosine-1-
phosphate and ceramide-1-phosphate [28,29], are regarded as
signalling substances. Accordingly, the benefit of pharmacologi-
cal interference with sphingolipid-mediated processes has been
investigated for several diseases [30,31].
Not only sphingolipids–including the signalling substances
sphingosine-1-phosphate and ceramide–contribute to many phy-
siological and pathological processes, but also the proteins
operating in the sphingolipid pathway can serve different functions.
For example, sphingolipid activator proteins are required for the
presentation of lipid antigens to CD1 molecules [32].
1.2. Biosynthesis
The first steps of glycosphingolipid biosynthesis lead to the
formation of ceramide at the cytoplasmic face of the ER
Fig. 1. Structures of ganglioside GM2, bis(monoacylglycero)phosphate (BMP, LBPA), sphingomyelin, and ceramide.
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Golgi apparatus with the aid of a transfer protein, CERT [34].
On the cytosolic leaflet of the Golgi membrane, glucosylcer-
amide is formed and translocated to the luminal face,
presumably by multidrug transporters [35,36]. Subsequent
glycosidation reactions are catalyzed by glycosyltransferases
in the Golgi apparatus [37,38]. In the case of gangliosides, the
limited specificity of some of the transferases [39] gives rise to
complex patterns on the cell surface within a combinatorial
biosynthetic pathway [40]. Genetically modified mice deficient
in glucosylceramide synthase die as early as embryonic day 7.5
[41], indicating a role of glucosylceramide or higher glyco-
sphingolipids in embryogenesis. In most cell types, de novo-
biosynthesis constitutes only a minor pathway for sphingolipid
formation; metabolic labelling studies indicate that the majority
of glycosphingolipids are formed by the recycling of building
blocks within a salvage-pathway [42]. After their biosynthesis,
glycosphingolipids reach the plasma membrane through
vesicular exocytotic membrane flow.
By far, most of the human diseases associated with
sphingolipid metabolism are degradation disorders. There areonly a few human diseases known so far that are caused by
alteration of biosynthetic enzymes. Hereditary sensory neuro-
pathy, type I, is caused by mutations in the SPTLC1 gene
leading to an increase in serine palmitoyltransferase activity,
subsequent elevation of ceramide levels, and enhanced neuronal
apoptosis [43,44]. A deficiency of a biosynthetic enzyme
associated with a human disease is reported for lactosylcer-
amide α2,3 sialyltransferase (GM3-synthase). Deficiency of
this enzyme causes an autosomal recessive infantile-onset
symptomatic epilepsy syndrome [45]. There is also some
evidence that type 9 of the neuronal ceroid lipofuscinosis might
be caused by a defect of a sphinganine acyltransferase regulator
protein and subsequent impairment of dihydroceramide bio-
synthesis [46].
2. Glycosphingolipid catabolism
The lysosomal degradation of membranes requires transport
and lipid sorting steps, before glycosphingolipids and other
membrane components can be degraded [47]. The cleavage
products, monosaccharides, sialic acid, fatty acids, and
2060 T. Kolter, K. Sandhoff / Biochimica et Biophysica Acta 1758 (2006) 2057–2079sphingosine, are able to leave the lysosome. This is mainly
facilitated by transporters localized in the endosomal and
lysosomal perimeter membranes.
2.1. Topology
Lysosomes digest extracellular and intracellular macromo-
lecules that enter the organelle by endocytosis, phagocytosis, or
autophagy. Plasma membrane components reach the lysosomal
compartment via endocytotic vesicular flow [48], either as
intraendosomal and intralysosomal membranes, or as part of the
limiting membrane [49] (Fig. 2). Both membrane pools differ in
their lipid and protein composition. The major part of
membrane digestion proceeds on the surface of internal
membrane structures. In contrast to this pool, the perimeter
membrane is protected from degradation by a glycocalix (Fig. 2)
composed of glycoproteins amply glycosylated with lactosa-
mine units [50]. Intraendosomal and intralysosomal mem-
branes of appropriate lipid composition can be degraded by
lysosomal hydrolases in the presence of sphingolipid activator
proteins and other lipid transfer proteins.
These internal membranes have been initially observed in
cells from patients with sphingolipid storage diseases such as
GM1 gangliosidosis [51] or combined sphingolipid activator
protein deficiency [52], where they accumulate as multi-
vesicular storage bodies. Sphingolipid activator proteins are
required for membrane digestion, therefore, the essentials of
lysosomal glycolipid digestion [47] are briefly discussed here.Fig. 2. Endocytosis and lysosomal digestion of membranes. Glycosphingolipids
(GSL) are highlighted on the plasma membrane (PM) and on internal
membranes [47]. Parts of the plasma membrane including GSLs are
incorporated into the membrane of intraendosomal vesicles and membrane
structures during endocytosis. The vesicles reach the lysosomal compartment
when late endosomes are transiently fused with primary lysosomes. They are the
sites of membrane digestion. The lysosomal perimeter membrane is protected
from degradation by a thick glycocalix. EGFR: epidermal growth factor
receptor.2.2. Sphingolipid activator proteins
Monosaccharide residues from the nonreducing end of the
oligosaccharide part of the glycosphingolipids are sequentially
cleaved off by the action of acid exohydrolases. The substrates
of these enzymes are embedded in intraendosomal and
intralysosomal membranes [53–55], whereas the enzymes are
dissolved in the lysosol. In vivo, GSLs with less than four sugar
residues [56] are only degraded in the presence of sphingolipid
activator proteins (SAPs). In vitro, these SAPs can often be
replaced by detergents. SAPs mediate the interaction between
the membrane bound lipid substrate and the water-soluble
enzyme or activate the enzyme directly. In vivo, enzymatic
hydrolysis of most membrane-bound sphingolipids is also
stimulated by anionic lysosomal lipids, especially by bis-
(monoacylglycero)-phosphate (BMP, lysobisphosphatidic
acid), which concentrates in the inner membranes of lysosomes
[57]. As indicated in Fig. 3, many catabolic reactions in this
pathway require the presence of an activator protein.
To date, five sphingolipid activator proteins (SAPs) are
known: the GM2 activator protein and the four saposins (Saps)
-A, -B, -C, and -D [79]. The GM2-activator is an essential
cofactor in the in-vivo degradation of ganglioside GM2 by β-
hexosaminidase A [58]; the inherited deficiency of this protein
leads to the AB variant of GM2 gangliosidoses (Fig. 4).
For the presentation of ganglioside GM2 or related glyco-
sphingolipids, e.g., GM1 [56], to the active site of the degrading
enzyme, the GM2-activator has to insert into the bilayer of
intralysosomal lipid vesicles. Results from in vitro experiments
indicate that the GM2-activator can insert into a model
membrane only below a critical lateral pressure of 15 to
25 mN/m [59]. The lipid recognition site of the activator
interacts with the substrate, so that the hydrophobic ceramide
portion of the substrate becomes embedded in the hydrophobic
cavity of the activator protein. After a conformational change of
the lipid-loaded activator increasing the water-solubility of the
complex, this is released from the membrane, and ganglioside
GM2 is presented to the enzyme and is subsequentially
degraded [60].
The Saps or saposins A–D are glycoproteins with molecular
weights of 8–11 kDa [79]. They belong to a family of saposin-
like proteins with lipid binding- and membrane perturbing
properties [32]. Although the four Saps share a high degree of
homology [61] and some properties, they act differentially and
show different specificity. This leads to the different phenotypes
of the different Sap deficiencies (see Section 3.12) Besides their
function as enzyme cofactors, sphingolipid activator proteins
play an important role in lipid antigen presentation. They
participate in the loading of lipid antigens to immunoreceptors
such as human CD1b [62], human [63], and mouse CD1d [64].
2.3. Intralysosomal membranes
The degradation of intralysosomal membranes depends on
their lipid composition. Intralysosomal membranes, but not the
lysosomal perimeter membrane, are enriched in bis-(mono-
acylglycero)-phosphate (BMP), which is biosynthetically
Fig. 3. Degradation of selected sphingolipids in the lysosomes of the cells [47]. The eponyms of individual inherited diseases are given. Activator proteins required for
the respective degradation step in vivo are indicated. Variant AB, AB variant of GM2 gangliosidosis (deficiency of GM2-activator protein); Sap, saposin.
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cardiolipin, [65,66] presumably on the surface of these vesicles.
Due to its unusual sn1,sn1′-configuration, BMP has a
sufficiently long lifetime in spite of the presence of the
lysosomal phospholipases [67]. Other anionic lipids like
phosphatidylinositol [68] and dolichol phosphate [69], albeit
in smaller amounts than BMP, are also found within the
lysosomal compartment. Furthermore, cholesterol is almost
absent in lysosomes [57]. High amounts of BMP and low
amounts of cholesterol in internal lysosomal membranes appear
to be required for the degradation of glycosphingolipids.Fig. 4. Model of GM2-activator-stimulated hydrolysis of ganglioside GM2 by hu
hydrophobic (V90-W94 and V153-L163) surface loops and a single short helix. The
cavity allowing both, an open and closed conformation. GM2AP=GM2-activator pDecreasing amounts of cholesterol in artificial vesicles increase
the membrane-perturbing capability of Sap-A (Locatelli Hoops,
S., Klingenstein, R. and Sandhoff, K., unpublished), Sap-B, and
Sap-D (Remmel, N. and Sandhoff, K., unpublished). The pre-
sence of BMP in these vesicles increases the ability of the GM2-
activator [70], Sap-B, and Sap-D (Remmel, N. and Sandhoff, K.,
unpublished) to solubilize lipids. BMP also stimulates degrada-
tion of sphingomyelin by acid sphingomyelinase [186],
ceramide by acid ceramidase [198], and glucosylceramide by
glucosylceramide-β-glucosidase [137]. In addition, nega-
tively charged lysosomal lipids drastically stimulate theman β-hexosaminidase A [60]. The glycolipid binding site is lined by two
most flexible of the loops (V153-L163) controls the entrance to the hydrophobic
rotein, Hex A=β-hexosaminidase A.
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by GM1-β-galactosidase [137]. A similar stimulation was
demonstrated for the degradation of ganglioside GM2 by β-
hexosaminidase A [70], and for the sulfated gangliotriao-
sylceramide SM2 by β-hexosaminidases A and S [103] in
the presence of the GM2-activator protein. Furthermore, in
the presence of Sap-C, a drastic enhancement of glucosyl-
ceramide degradation by glucosylceramide-β-glucosidase can
be produced by negatively charged model lipids such as phos-
phatidylserine, phosphatidylglycerol, and phosphatidic acid
[71,72,133].
3. Sphingolipidoses
Together with mucopolysaccharidoses, mucolipidoses, gly-
coprotein, and glycogen storage diseases, sphingolipidoses
belong to the lysosomal storage diseases (LSDs) [73–77]. With
a collective frequency of 1 in 7000–8000 live births [78], the
LSDs are rare disorders. About 40 genetically different forms
are known. Defects in enzymes, cofactors (such as sphingolipid
activator proteins [79]), but also in the targeting or transport
systems involved in the degradation process can lead to a LSD.
The sphingolipidoses [80] are a group of inherited diseases,
which are caused by defects in genes encoding proteins
involved in the lysosomal degradation of sphingolipids. The
diseases are usually named according to the identity of the
storage material [75,81]. The mode of inheritance is autosomal
recessive with the exception of Fabry disease [115]. According
to the strictly sequential degradation pathway of glycosphingo-
lipids in humans, defects for almost every step in the
degradation of these lipids have been described. An exception
is the degradation of lactosylceramide, which can be degraded
by two different enzyme/activator systems [82]. Therefore, no
single enzyme defect is known that leads to isolated
lactosylceramide storage. Together with other sphingolipids,
however, lactosylceramide accumulates when various cofactors
are absent, as it is the case in prosaposin deficiency [209].
Most enzymes and cofactors deficient in the sphingolipi-
doses have been characterized, their genes have been cloned,
and animal models of most of the sphingolipidoses have been
created by targeted disruption of the respective genes in mice
[83,84]. Although many of the different sphingolipidoses have
been sub-classified into types that differ in course and onset,
there is a clinical continuum for these diseases. As it will be
discussed below, this is largely caused by differences in the
residual activities of the defective proteins.
3.1. GM1-gangliosidosis
GM1-gangliosidosis is caused by an inherited deficiency of
the lysosomal enzyme GM1-β-galactosidase [85,86]. GM1-β-
galactosidase is a protein of 64 kDa, which is derived from an
88-kDa precursor (review: [86]). It occurs as part of a lysosomal
multienzyme complex, together with sialidase, the so-called
protective protein [87], cathepsin A, and N-acetylaminogalacto-
6-sulfate sulfatase [88]. GM1-β-galactosidase catalyses the
hydrolysis of ganglioside GM1 to GM2 in the presence of eitherthe GM2-activator protein or Sap-B [56]. According to the
substrate specificity of the variant enzyme, an inherited defect
can also lead to another disorder, Morquio disease, type B.
Storage of galactosylceramide-β-galactosidase substrates,
galactosylceramide and lactosylceramide, does not occur.
Three clinical forms of GM1-gangliosidosis can be distin-
guished: In infantile (type 1) GM1-gangliosidosis, develop-
mental arrest and progressive deterioration of the nervous
system occur in early infancy. Characteristic symptoms are
exaggerated startle responses to sound, a macular cherry-red
spot, hepatosplenomegaly, rigospasticity associated with sei-
zures, and generalized skeletal dysplasia. Most patients die
within the first 2 years of life.
The late infantile/juvenile form (type 2) is characterized by
progressive neurologic symptoms in children, and the adult/
chronic form (type 3) occurs in young adults. In adults,
extrapyramidal signs frequently presenting as dystonia are the
most common neurologic manifestations. Dysmorphic changes
are less prominent or absent in these clinical forms.
Apart from the ganglioside GM1, other enzyme substrates
also accumulate, such as glycolipid GA1 [89], oligosaccharides
from glycoproteins, and intermediates of keratan sulfate
degradation. These substances are stored in different organs,
according to their major site of biosynthesis. Massive lysosomal
GM1-storage in neurons leads to degeneration of the nervous
system. On the other hand, formation of meganeurites and
ectopic dendrogenesis are presumably due to the antineurotoxic
[90], neuroprotective, and neurorestorative properties of gang-
lioside GM1 in the plasma membrane. Like in other storage
diseases, a neuroinflammatory response has been implicated in
the pathogenesis of GM1-gangliosidosis [249]. Like in other
neurodegenerative diseases [258], an unfolded protein response
has been identified in the mouse model of the disease [91]:
Mislocalized GM1 activates ER-chaperones and leads to
neuronal apoptosis. The severity and progression of the disease
correlates with the residual enzymatic activity in cells and body
fluids [92].
Gene mutations identified in GM1 gangliosidosis and
Morquio B disease include missense/nonsense mutations,
duplications/insertions, and insertions causing splicing defects.
Neither the type, nor the location of mutations in the gene of
GM1-β-galactosidase could be correlated to the phenotype of
the patients. Also, mutations within the protective protein can
cause accumulation of ganglioside GM1 via destabilization of
the β-galactosidase. An engineered mouse model resembling
the neurological phenotype of human GM1-gangliosidosis is
available [93]. Spontaneous animal models of this disease, such
as feline and canine, are also known [86]. A successful
treatment of this disease is not available to date; bone marrow
transplantation did not correct the neurological phenotype of the
juvenile variant of the disease [94]. A chemical chaperone
therapy for the brain pathology has been suggested [95], and
substrate reduction therapy reduces storage levels in the brain of
the mouse model of the disease [96].
Morquio type B disease clinically resembles a mild
phenotype of Morquio A disease, where keratan sulfate
accumulates due to N-acetylgalactosamine-6-sulfatase
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the inherited defect of GM1-β-galactosidase. It is characterized
by the predominant storage of keratan sulfate and oligosacchar-
ides with terminal galactose residues. Patients show generalized
skeletal dysplasia. Involvement of the nervous system and
hepatosplenomegaly are absent. The differences between GM1
gangliosidosis and Morquio B disease can be attributed to a
lower affinity and activity of β-galactosidase variants towards
substrates with Gal-β1,4-GlcNAc motifs in Morquio patients
compared to the Gal-β1,3-GalNAc motive present in ganglio-
side GM1 [97].
3.2. GM2-gangliosidoses
The GM2-Gangliosidoses [98,99] are caused by defects in
degradation of ganglioside GM2 and related glycolipids leading
to accumulation of these lipids, most fatally in neuronal cells.
GM2 is degraded by cleavage of the β-glycosidic linkage
between the N-acetylgalactosaminyl residue and the galactose
residue by β-hexosaminidases. This reaction requires the GM2
activator protein in vivo. The three lysosomal β-hexosamini-
dases differ in the combination of their two subunits (α and β),
and in their substrate specificity. β-Hexosaminidase A (αβ)
cleaves off terminal β-glycosidically linked N-acetylglucosa-
mine- and N-acetylgalactosamine residues from negatively
charged and uncharged glycoconjugates by a retaining double-
displacement mechanism. The enzyme has two active sites, one
on the α-chain, and the other on the β-chain [100]. β-
Hexosaminidase B (ββ) predominantly cleaves uncharged
substrates like glycolipid GA2 and oligosaccharides with
terminal N-acetylhexosamine residues. The crystal structure of
human β-hexosaminidase B [101,102] has been solved and
shows the twoactive sites at thehomodimer interface,wheremost
of the alterations due tomutations leading to Sandhoff disease are
located. β-Hexosaminidase S (αα)) is of secondary significance
for GM2 degradation, but it contributes to the degradation of
glycosaminoglycans and sulfated glycolipids [103].
The inborn deficiency of the GM2-activator as well as the
deficiency of the α- or β-chain of the β-hexosaminidase
isoenzymes leads to one of the three different variants of this
disease that are named according to the isoenzyme remaining
intact. The B-variant is due to an α-chain deficiency, and the
subsequent deficiency of hexosaminidases A and S, but with
normal hexosaminidase B. Its infantile form is usually called
Tay–Sachs disease [104]. The 0-variant, or Sandhoff disease, is
caused by the deficiency of the β-chain and the resulting
deficient activity of β-hexosaminidases A and B, but remaining
activity of β-hexosaminidase S. The AB-variant is a conse-
quence of mutations in the GM2-activator gene and is
characterized by normal activities of β-hexosaminidase A, -B,
and -S towards the natural substrate GM2 in detergent-
containing enzyme assays.
3.3. Tay–Sachs disease
Clinically, the B-variant of GM2-gangliosidoses can be
subclassified into infantile, juvenile, chronic, and adult onset forms.The infantile form, known as Tay–Sachs disease, has a higher
prevalence among Ashkenazi Jews with a heterozygote
frequency of 1:27. Affected children are normal at birth and
show first symptoms, such as mild motor weakness and
increased startle reaction between 3 and 6 months of life.
Weakness, hypotonia, poor head control, and decreasing
attentiveness are observed and visual symptoms appear. A
finding in most cases is a cherry red spot in the central retina of
the patients. Motor, mental and visual abilities decline rapidly
after about 10 month of age. Macrocephaly and seizures are
common in the second year. Further deteriorations lead to a
vegetative state. Death often occurs between the second and
fourth year of life.
In the juvenile form, the first motor symptoms are noted
between 2 and 6 years of age, and death occurs at the age of 10
to 15 years. At the end of the first decade, loss of speech,
increasing spasticity, seizures, loss of vision, and progressive
dementia are common manifestations. A vegetative state is
finally reached and the patients die frequently as a consequence
of intercurrent infections.
In the chronic form, clinical onset is between 2 and 5 years of
age. Symptoms include abnormalities in gait and posture. With
advanced age, distinct neurological symptoms appear. Mental
and verbal intelligence as well as sensory modalities remain
intact. The patients can reach an age of 40 years.
In the adult form, the symptoms are very heterogeneous.
Neurological disorders such as spinal muscular atrophy and
psychoses may be mimicked. Nevertheless, intelligence and
visual capability are not affected.
The B1-variant of GM2-gangliosidoses [105,106] differs
enzymatically from the B-variant by an altered substrate
specificity of the mutated β-hexosaminidase A. While no
activity is detected towards the natural substrate ganglioside
GM2 and negatively charged synthetic substrates, synthetic
uncharged substrates used for diagnosis are cleaved. The
function of the α-chain active site is defective, whereas subunit
association, enzyme processing, and the activity of the β-chain
are not impaired. Homozygous patients with the B1-mutation
show the course of the juvenile disease. However, a late
infantile course was seen in compound heterozygotes with a B1
and a null allele.
3.4. Sandhoff disease
The 0-variant of GM2-gangliosidosis was the first gang-
liosidosis for which the underlying enzymatic defect was
identified. It is characterized by storage of negatively charged
glycolipids characteristic for Tay–Sachs disease, but also by
elevation of uncharged glycolipids such as glycolipid GA2 in
the brain and globoside in visceral organs [107]. Clinically, the
following forms have been reported:
Infantile Sandhoff disease: In addition to the clinical and
pathological manifestations present in Tay–Sachs disease
(infantile B-variant), organomegaly and slight bone deforma-
tions may also occur.
Juvenile Sandhoff disease: first symptoms such as slurred
speech, cerebellar ataxia, and psychomotor retardation appear at
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mental function deteriorates gradually.
Adult Sandhoff disease: The onset of symptoms is delayed to
late adult life. The clinical manifestations in this chronic variant
are similar to those of Tay–Sachs disease variants of
corresponding ages, with the exception of additional accumula-
tion of uncharged enzyme substrates.
3.5. AB-variant of GM2-gangliosidosis
In this variant, the deficiency of the GM2 activator protein
[108] in the presence of normal β-hexosaminidase A, B, and S
activity leads to the accumulation of glycolipids GM2 and GA2.
The clinical picture resembles that of Tay–Sachs disease with a
delayed appearance of symptoms.
Histopathologically, the GM2-gangliosidoses are character-
ized by the presence of swollen neurons with massive
accumulation of storage material in membranous cytoplasmic
bodies throughout the central and peripheral nervous system.
The pathogenesis of the GM2-gangliosidoses is not
completely understood. Together with other membrane lipids
and proteins, ganglioside GM2 accumulates and precipitates
within the lysosomes of cells [99], particularly in neuronal cell
bodies. Although the storage compounds themselves are neither
toxic nor immunogenic, they induce inflammatory responses as
demonstrated for glycoconjugates in the murine model of
Sandhoff disease [109]. The toxic derivative lysoganglioside
GM2 was found in patients with GM2-gangliosidosis [110,111].
It is not clear, however, if this contributes to the pathogenesis of
the disease. The induction of misconnections in neuronal
dendrites and other cellular processes might be one of the causes
of the neurological phenotype. Undegraded storage material
might reach, to some extent, cellular membranes like that of the
Golgi apparatus or the plasma membrane, and alter membrane
composition and function. Bone marrow transplantation (BMT)
experiments suggest a complex pathogenetic mechanism that
may well involve lytic compounds, for example, in the blood
circulation and/or cytokines generated in the brain [112].
The severity of the disease correlates with the residual
activity of the defective enzymes [231]. Mutations in the genes
encoding the three polypeptide chains have been identified [98].
Naturally occurring animal models of GM2-gangliosidoses
have been reported in dogs, cats and pig. In addition, murine
models of Tay–Sachs disease, Sandhoff disease and GM2-
activator deficiency have been generated using gene-targeting
techniques [98]. Unlike human GM2 gangliosidoses, the
phenotypes of these murine models differ greatly. These
differences among the models result from different ganglioside
degradation pathways in mice and humans. In mice, the
defective step can be bypassed by the action of a sialidase
[113]. An inducible mouse model of the late-onset B-variant has
been established [114]. To date, a therapy attenuating the
development or reversing the clinical manifestations of the
GM2 gangliosidoses is not available, but several therapeutic
strategies are studied clinically and in disease models (Section
6). Treatment is restricted to supportive care and appropriate
management of the intervening problems.3.6. Fabry disease
Fabry disease is an inborn deficiency of lysosomal α-
galactosidase A. This homodimer of 50 kDa subunits [115]
catalyses the lysosomal hydrolysis of globotriaosylceramide.
Fabry disease is a panethnic, X-chromosomal-linked inherited
disorder with an estimated frequency of 1:117,000 [78] to
1:40,000 birth [115]. Hemizygous males have extensive
deposition of globotriaosylceramide in the lysosomes of
endothelial, perithelial, and smooth-muscle cells of blood
vessels. Many cell types in the heart, kidneys, eyes, cornea,
and the autonomous nervous system are also affected.
The first clinical symptoms usually occur during childhood
or adolescence. These include severe pain in the extremities,
vascular cutaneous lesions, hypohidrosis, and corneal and
lenticular opacities. The disease develops to renal, cardiac, and/
or cerebral complications, which are the most common causes
of death in the 4th or 5th decade of life. A variant of the disease
characterized by a milder progression and a primary impairment
of the heart muscle has been attributed to enhanced residual
activity of more than 5% of normal of the defective enzyme.
Heterozygous females have higher residual α-galactosidase A
activities, have an attenuated form of this disease, and are
usually not as severely affected as hemizygous males. Diagnosis
of female patients is facilitated by determination of the α-
galactosidase A to β-glucuronidase ratio [116].
The observed symptoms result from accumulating
glycolipids in the affected tissues, the blockage of blood
vessels, or both simultaneously. For example in the kidney,
the lesions are due to glycosphingolipid accumulation in
several cell types, but renal blood vessels are progressively
and often extensively involved. On the other hand, in the
nervous system vascular involvement is the predominant
cause of the affection.
About 180 different mutations causing Fabry disease have
been identified including partial gene rearrangements, splice-
junction defects, and point mutations [115].
An animal model of this disease has been created [117].
Although it shows no clinical symptoms, it allows evaluation of
therapeutic strategies, as for treatment using adeno-associated
virus mediated therapy, which leads to long-term correction of
storage [118]. The treatment of Fabry disease by enzyme
replacement therapy using recombinant α-galactosidase A
derived from human skin fibroblasts [119] or CHO-cells [120]
has been established. A chemical chaperone approach with
galactose was successful in a male patient of the cardiac variant
of the disease [121], and extensions of this approach using
inhibitors have been reported [122–124]. Deoxygalactonojir-
imycin treatment of knock-in mice that express the (R301Q)
variant of α-galactosidase A led to an increase of enzyme
activity in the heart and reduction of globotriaosylceramide
storage [125].
3.7. Gaucher disease
Gaucher disease is the most common form of the
sphingolipidoses [126,127,130]. It is caused by the deficiency
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mulation of glucosylceramide.
Glucosylceramide-β-glucosidase, also called glucocerebro-
sidase, consists of 497 amino acids and has a molecular weight
of about 65 kDa in its glycosylated form [130]. It is a lysosomal
enzyme that can associate to membranes. The X-ray structure of
this enzyme has been reported [131], also when it was bound to
the irreversibly acting inhibitor conduritol β-epoxide [132].
Variant forms of the enzymes with 42 selected single amino acid
substitutions have been generated, expressed in insect cells,
purified, characterized for kinetic, stability and activator
response properties, and mapped onto the crystal structure
[133]. The enzyme can be allosterically activated by Sap-C
[134,135] and by negatively charged phospholipids [136], of
which the lysosomal bis(monoacylglycero)phosphate seems to
be of physiological relevance [137].
Three different types of Gaucher disease are distinguished:
The attenuated form, Gaucher disease type I, has a nonneuro-
pathic course and is the most frequent form of this disease. It has
a frequency of 1: 50000–200000 births, but which is higher
amongst Ashkenazi Jewish population (1:1000). Life expec-
tancies of these patients range between 6 and 80 years. Gaucher
disease type II, the acute form, is a very rare panethnic disease
characterized by the involvement of the nervous system with
early onset and a life expectancy of less than two years. The
subacute or juvenile form, Gaucher disease type III, is an
intermediate variant of the other two types, mainly found in the
Northern Swedish population. In this case, the neurological
symptoms have a later onset and a slower development than in
form II; the survival age of the patients is between a few years
and four decades. A partial defect in glucosylceramide-β-
glucosidase is not associated with visible skin phenotype in
humans, but complete enzyme deficiency leads to the
“collodion baby” phenotype with a severe impairment of skin
function [138].
In all variants, patients may show hepatosplenomegaly,
anemia, thrombocytopenia, and bone damage. The severity of
these symptoms differ widely, but is inversely correlated with
the residual enzyme activity determined in skin fibroblasts of
Gaucher patients [139].
Even if the enzyme activity is reduced in all cell types, the
phenotype of type 1 of the disease is predominantly manifested
in macrophages of the reticuloendothelial system, since these
cells have to degrade large amounts of glycolipids derived from
the phagocytosis of erythrocytes. Due to the stored material,
macrophages acquire a typical morphology, which is character-
ized by the enlargement of the cell and the occurrence of
cytoplasmic linear inclusions. Not only the appearance of these
so called “Gaucher cells” in the affected tissues, but also the
inflammatory response they induce by the release of cytokines
[140], might account for the hypertrophy of the affected organs,
for cortical bone loss, and bone marrow disease. Types II and III
of the disease that affect the CNS are characterized by a
progressive loss of neuronal cells. This might also be caused by
accumulation of glucosylsphingosine, which apparently pro-
duces neuronal toxicity [141,243] and might be also able to
induce inflammatory responses [142].Together with glucosylceramide accumulation, an elevation
of chitotriosidase activity occurs in plasma that can be used for
diagnostic purposes [143].
Approximately 200 mutations at the glucosylceramide-β-
glucosidase locus have been found in patients with Gaucher
disease, four of which account for about 86% of the cases in the
Jewish population and for 68% in non-Jewish population. Two
cases of Gaucher disease are known, where the cause is the
absence of a sphingolipid activator protein, Sap-C [144,225,
226]. A certainmutation (N370S) impairs the interaction of variant
glucosylceramide-β-glucosidase enzyme with Sap-C [145].
An animal model most resembling the type II form of the
disease has been created by targeted disruption of the
glucosylceramide-β-glucosidase gene in mice [146]. The
animals store glucosylceramide in cells of the reticuloendothe-
lial system and die within 24 h after birth. Recently, additional
viable models of Gaucher disease have been developed by
introduction of the point mutations N370S, V394L, D409H, or
D409V into the mouse glucosylceramide-β-glucosidase locus
[147]. Glucosylceramide-β-glucosidase activities were in the
range of 2 to 25% of wild type; the homozygous N370S mice
were not viable, and the others showed variable pathologies.
Due to the pioneering work of R. O. Brady, enzyme therapy
for the attenuated form of Gaucher disease (type I) is available
[148]. It consists of the use of glucosylceramide-β-glucosidase
purified from placenta or recombinantly expressed, which has
been modified in the carbohydrate part to contain targeting
information for the mannose receptor on macrophages [149].
After treatment of the patients, a normalization of the blood
parameters, as well as a reduced weight of liver and spleen can
be observed. Due to CNS involvement, enzyme replacement is
less promising for types 2 and 3 of the disease [150]. Also bone
marrow transplantations have been accomplished, with variable
results [151–153]. A serious problem is the reversal of bone
involvement, which has been overcome by peripheral blood
stem cell transplantation in the animal model [154].
3.8. Metachromatic leukodystrophy
Metachromatic Leukodystrophy (MLD) is caused by the
inherited deficiency of arylsulfatase A (ASA) and the
accumulation of sulfatide in several tissues [155]. The storage
material accounts for the observed metachromatic staining
[156,157]. MLD is a rare disease with an estimated frequency
between 1:40000 and 1:100000 in newborns. Arylsulfatase A
[157] catalyses the conversion of sulfatide into galactosylcer-
amide and sulfate. For this process, the assistance of Sap-B is
required [158]. MLD can be classified into a late infantile, a
juvenile, and an adult form.
In the late infantile form, symptoms develop between 6
months and 4 years of age, and death usually occurs about 5
years later. It begins with hypotonia, unsteady gait, and mental
regression. Several abilities progressively deteriorate. Common
symptoms are loss of speech, blindness, quadriparesis,
peripheral neuropathy, and seizures. In a final stage before
death, the child is bedridden, in a decerebrate state, and looses
all contact with his/her surroundings.
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ranging from 4 to 16 years and death usually before 20 years.
The adult form can begin after puberty up to the 6th decade
of life and may extend for a few years or for decades. This form
is less frequent than the previous two. In both cases, patients
show gradual deterioration in school or job performance, with
emotional and behavioral disturbances or psychiatric symptoms
in the adult form. Other clinical manifestations are gait
clumsiness, incontinence, and optic atrophy. During the final
stages of this disease, the patient reaches a vegetative state.
The biochemical defect in all forms of MLD is a deficiency
in the enzymatic hydrolysis of sulfatides. These sulfated
glycolipids occur mainly in the myelin sheaths in the white
matter of the brain, in the peripheral nervous system, and in the
kidney tissue. The clinical and histopathologic manifestations
of MLD are fundamentally caused by a demyelination process.
This phenomenon appears to be secondary to sulfatide-induced
changes in oligodendrocytes and Schwann cells.
Additionally, lysosulfatide, a cytotoxic sulfatide derivative
that occurs in tissues of the patients, seems to play a role in the
pathogenesis of this disease [244].
More than 60 different mutations in the ASA gene are
associated with the MLD phenotype. Some mutations produce a
complete loss of enzyme activity and patients homozygous for
this type of allele develop the late infantile form of the disease.
On the other hand, low but definite amounts of ASA activity
result in milder forms of the disease [159,160,231].
Also the inherited deficiency of Sap-B, the cofactor required
for sulfatide cleavage by ASA in vivo, leads to a clinical picture
similar to MLD caused by ASA deficiency. In this case, the
activity of ASA toward soluble, synthetic substrates is normal
[161].
A mouse model of MLD has been created [162]. Although it
develops some neurologic symptoms, most likely due to
sulfatide storage, the mice show no demyelination, which is a
hallmark of the human disease. Although it shows only a low
extent of neurological and neuropathological changes, this
model was of value for characterization of defects in acoustic
perception. To date there is no causal therapy for this lethal
disease, but enzyme replacement therapy has been successfully
evaluated in the animal model: In ASA knockout mice,
intravenous ASA injection restored sulfatide metabolism in
peripheral tissues and the central nervous system [163]. Also
bone marrow transplantation has been applied to patients of the
juvenile form [164]. Transplantation of genetically modified
stem cells gave promising results in the nervous system of the
animal model [165].
In a related disease, multiple sulfatase deficiency known
as mucosulfatidosis or Austin disease, the activities of all
known sulfatases are strongly reduced [166]. This disease
results from a defective posttranslational modification, which
is necessary to enable sulfate ester hydrolysis by sulfatases.
Cells from these patients show a deficient transformation of
a cysteine residue into a formylglycine residue in the active
site of different sulfatases [167]. The phenotype of this
disease can be described as a combination of symptoms of
metachromatic leukodystrophy and a mucopolysaccharidosis.Nine mutations in the sulfatase-modifying factor-I gene
(SUMFI) of seven patients have been identified that lead to
deficiency of the Cα-formylglycine generating enzyme
(FGE) [168].
3.9. Krabbe disease
Krabbe disease or globoid cell leukodystrophy [169,170] is
caused by an inherited deficiency of galactosylceramide-β-
galactosidase. This membrane-associated enzyme with a
molecular weight of about 50 kDa hydrolyzes galactosylcer-
amide to ceramide and galactose [170]. Sap-A and Sap-C are
able to stimulate this degradation step in vivo. Although there is
some storage especially in globoid cells, the enzyme deficiency
does not lead to substantial substrate accumulation, probably
because of the rapid loss of galactosylceramide synthesizing
and accumulating cells. Krabbe disease and MLD are classical
myelin diseases.
Clinically, Krabbe disease has two variants: an infantile and a
late onset form.
Symptoms of the infantile form usually start between 3 and 6
months of life, and may include irritability or hypersensitivity to
external stimuli. Within a short time, severe mental and motor
deteriorations occur. Commonly, patients become blind, deaf,
flaccid, and hypotonic. The survival of the patients is less than
two years.
In the late onset form of globoid cell leukodystrophy, the
symptoms can appear at any time after the patients are able to
walk; the onset may vary from a few years up to 73 years of age.
Common clinical manifestations are psychomotor retardation,
blindness, spastic paraparesis, and dementia.
The most characteristic histopathological changes are
extensive demyelination, loss of oligodendroglia, astrogliosis,
and presence of numerous multinucleated globoid cells. These
cells are hematogenous macrophages containing undigested
galactosylceramide.
The pathogenesis of this disease can be attributed to a
combination of two phenomena: the impaired degradation of
galactosylceramide, which leads to globoid cell infiltration, and
the accumulation of the cytotoxic derivative galactosylsphin-
gosine (lysogalactosylceramide=psychosine), which causes
oligodendroglial cell destruction. Psychosine is another sub-
strate of the deficient enzyme; it accumulates up to toxic, cell-
destructive levels. Several mutations in the galactosylceramide-
β-galactosidase gene have been identified. A deletion of exons
11–17 is a very frequent mutation and is associated with the
infantile form of the disease [171,172].
An authentic mouse model for Krabbe disease is the twitcher
mouse with a premature stop codon within the coding sequence
of the gene [173]. Another animal model carries a mutation on
the galactosylceramide-β-galactosidase gene leading to low
enzyme activity [174]. Investigations of the twitcher mouse
point to a neuroinflammatory response that might additionally
contribute to pathogenesis [175,176]. A double knockout
mouse deficient in galactosylceramide-β-galactosidase and the
biosynthetic enzyme ceramide galactosyltransferase (cgt)
shows shorter lifespan than the (cgt −/−)mice themselves [177].
2067T. Kolter, K. Sandhoff / Biochimica et Biophysica Acta 1758 (2006) 2057–2079Amutation within the Sap-A domain of the human [215] and
murine [214] Sap-precursor protein causes a deficiency of the
mature activator and a phenotype similar to Krabbe disease.
To date, treatment of Krabbe disease is limited to bone
marrow transplantation in patients with only minimal neurolo-
gic involvement [267,268]. In infantile patients, transplantation
of umbilical-cord blood gave promising results, but only when
the treatment was started before the onset of symptoms [178].
Recently, peripheral enzyme replacement has been applied to
Twitcher mice, which resulted in attenuation of early symptoms
and an increase of life span [179].
3.10. Niemann–Pick disease, type A and B
Niemann–Pick disease (NPD), type A and B, is caused by
the inherited deficiency of acid sphingomyelinase (ASM) and
accumulation of sphingomyelin [184]. Secondarily, sphingo-
myelin also accumulates in Niemann–Pick disease, type C, in
which the products of the NPC-1 or NPC2 genes are deficient
[180,181]. In both cases, trafficking of endocytosed cholesterol
is altered. Also drug-induced lysosomal storage of sphingo-
myelin occurs in response to treatment of human patients with
tricyclic antidepressants over long time periods. In this case.
sphingomyelin accumulates due to the drug-induced degrada-
tion of acid-sphingomyelinase [182,183].
Acid sphingomyelinase [184,185] is a glycoprotein with a
molecular weight of 70 kDa. Within the lysosomes, it catalyses
the degradation of sphingomyelin to ceramide and phosphor-
ylcholine. Its modular structure includes a Sap-like domain and
a catalytic domain. Acid sphingomyelinase can be stimulated by
lysosomal lipids and sphingolipid activator proteins [186], but
this appears not to be necessary in vivo.
NPD, type A and B, is a panethnic disease with a higher
frequency among Ashkenazi Jews (1:80 for heterozygotes).
Type A NPD is a fatal disorder of infancy with a life expectancy
of the patients of 2 to 3 years. Affected newborns appear to be
normal at birth, but in the first few months of life, symptoms
such as hepatosplenomegaly, moderate lymphadenopathy,
hypotonia, and muscular weakness appear. Feeding difficulties
and splenomegaly lead to a decrease in linear growth and body
weight. In later stages of the disease, common manifestations
are microcytic anemia, decreased platelet count, osteoporosis,
brownish-yellow color of the skin, and cherry-red maculae.
Psychomotor retardation becomes evident by 6 months of age
and gradually increases over the years. In an advanced state, the
patient looses contact with the environment.
Type B NPD is a phenotypically variable disorder with little
or no involvement of the nervous system. It is usually diagnosed
in childhood, but patients can reach adulthood. Commonly, liver
and/or spleen are enlarged and progressive pulmonary infiltra-
tion causes the major disease complications in more severely
affected patients.
Patients with type B show a higher residual enzyme activity
than those with type A [187].
NPD is characterized by the presence of “foam cells” or
“Niemann–Pick cells”, although patients with other pathologies
may have histologically similar cells. The formation of thesehistiocytic cells is caused by storage of sphingomyelin and/or
other lipids in the monocyte–macrophage system. Storage
occurs in spleen and lymph nodes, but also in liver, brain,
kidney, and lungs. There is little or no lipid storage in the central
nervous system of type B NPD patients.
Sphingolipid-induced alterations in signal transduction [188]
might also contribute to NPD pathogenesis. In response to
extracellular stimuli, ceramide can be generated by hydrolysis
of sphingomyelin, catalyzed by different sphingomyelinases
with different topologies. Since in addition to neutral sphingo-
myelinases, ASM also might play a role in the activation of the
so-called “sphingomyelin pathway”, NPD patients may have
subtle abnormalities in various signaling pathways and these
abnormalities could be exacerbated by stress. There is currently
little clinical evidence in support of this hypothesis, however,
mice deficient in ASM show a severe impairment in early host
defense against Listeria monocytogenes [189] and other
signalling abnormalities.
Another factor that may contribute to the pathogenesis of the
disease is the formation of sphingosylphosphocholine (SPC), a
potent mitogen which can induce neurite outgrowth, and which
has been shown to accumulate in type A NPD [190].
Different mutations in the ASM gene that cause types A and
B NPD have been described. Three mutations, R496L, L302P,
and fsP330, account for about 92% of the mutant alleles in
Ashkenazi Jewish type A NPD patients. A common mutation in
type B patients is the single lesion ΔR608 [184].
Mouse models of NPD have been constructed by using gene-
targeting strategies [191,192]. Even if the precise targeting
events differed in the two animal strains, they show essentially
identical phenotypes. The NPD “knock-out” mice develop
features of both types A and B NPD, and are used for evaluation
of various therapeutic strategies. To date, there is no specific
treatment available for NPD. If performed early in life, BMT
has a positive effect on the clinical course of severely affected
type B NPD patients [193], but graft versus host disease and
other transplant-related complications are common and pre-
clude its use as a routine therapy. The outcome of BMT for the
treatment of type A patients is uncertain [194].
3.11. Farber disease
Farber-disease [195] is a rare disease due to the inherited
deficiency of lysosomal acid ceramidase and storage of
ceramide in the lysosomes. Acid ceramidase [195] is a
heterodimeric enzyme composed of an α-subunit of 13 kDa
and a β-subunit of 40 kDa [196]. Both subunits are derived
from a common 55 kDa precursor that is processed within late
endosomes and lysosomes [197]. Acid ceramidase catalyses the
degradation of ceramide to sphingosine and a fatty acid in the
lysosomes, and requires the presence of Sap-C [198] or Sap-D
[199]. It is also able to catalyze the reverse reaction [200]. Point
mutations on the acid ceramidase gene in patients of Farber
disease have been identified [197,201]; deletion of the gene
leads to embryonic lethality at day 8.5 in mice [202].
Usually, the symptoms of Farber disease appear several
months after birth, and death occurs within the first years of life.
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most characteristic clinical manifestation is the development of
painful and progressive joint deformations, subcutaneous nodules
(lipogranulomas), and progressive hoarseness. In the granulomas,
but also in some organs and tissues, lipid-loadenmacrophages are
frequent. Apart of skin and joints, liver, spleen, lung, and heart are
frequently affected organs. Neuronal accumulation of ceramide
and gangliosides has also been reported. A variant form of the
disease is present in prosaposin (=Sap-precursor) deficiency [79],
where the resulting deficiency also of Sap-D prevents ceramide
degradation [199]. The biochemical findings show combined
characteristics of Farber disease, and at least four other
sphingolipidoses (see Section 3.12.1.).
The important role of ceramide in skin function accounts for
the involvement of subcutaneous tissues in Farber disease. The
accumulated lysosomal ceramide in Farber disease does
apparently not cause apoptosis or another response expected
for this signaling substance [203]. The clinical course of this
disease correlates with the residual acid ceramidase activity
[204]. Therapy of infantile ceramidase deficiency has been
attempted with bone marrow transplantation, which improves
the peripheral, but not the neurological manifestations [205].
3.12. Deficiency of Saposins (Saps)
The sphingolipid activator proteins Sap-A, -B, -C, and -D are
different from the GM2-activator protein. However, the
deficiency of the latter protein was the first disease that was
attributed to the loss of a sphingolipid activator protein. See the
section on the AB-variant of the GM2-gangliosidoses.
3.12.1. Prosaposin
All four saposins are derived from a single protein, the Sap-
precursor, or prosaposin, a 70 kDa glycoprotein, which is
proteolytically processed to the mature activator proteins (Saps)
in the late endosomes and lysosomes [206–208]. Prosaposin is
detected mainly in brain, heart, muscle and body fluids, whereas
mature Saps are mainly found in liver, lung, kidney and spleen.
Until now, two different mutations in few human patients have
been reported, a homoallelic mutation of the start codon [209–
211] and a homoallelic deletion within the Sap-B domain,
which leads to a frame-shift and a premature stop codon [212].
The Sap-precursor deficiency is a fatal infantile storage
disorder, characterized by hepatosplenomegaly and severe
neurological symptoms. In all human patients, but also in the
Sap-precursor knockout mouse [213], there is simultaneous
storage of many sphingolipids, including ceramide, glucosylcer-
amide, lactosylceramide, ganglioside GM3, galactosylceramide,
sulfatides, digalactosylceramide, and globotriaosylceramide,
accompanied by an accumulation of intralysosomal membranes.
Prosaposin deficiency can be diagnosed by immunochemical
methods, by demonstration of a metabolic defect, or with
antisera against more than one Sap protein [238].
3.12.2. Sap-A
Sap-A is required for the degradation of galactosylceramide
by galactosylceramide-β-galactosidase in vivo. Mice carrying amutation in the Sap-A domain of the Sap-precursor protein
show accumulation of galactosylceramide and the late-onset
form of Krabbe disease [214]. Recently, a human disease has
been described that resembles Krabbe disease, but is caused by
a singular defect of Sap-A [215].
3.12.3. Sap-B deficiency
Sap-B is the first sphingolipid activator protein that was
identified [160]. It is a lipid-transport protein [216] which
shows a broader specificity than the GM2-activator. It is able
to stimulate the degradation of 20 glycolipids in the presence
of human, plant, and bacterial enzymes [217]. In vivo, it
mediates the degradation of sulfatide by arylsulfatase A, of
globotriaosylceramide and digalactosylceramide as demon-
strated in patients with Sap-B deficiency, where these
substrates accumulate in the urine [218]. It is also required
for the degradation of ganglioside GM3 and lactosylceramide,
as reported by studies in cultured human skin fibroblast of
Sap-B deficient patients [219]. The crystal structure of
unglycosylated human recombinant Sap-B has been solved
[220].
The inherited defect of Sap-B leads to an atypical form of
metachromatic leukodystrophy, with late infantile or juvenile
onset [221]. The disease is characterized by accumulation of
sulfatides, digalactosylceramide, and globotriaosylceramide
[79]. The clinical findings in Sap-B deficiency are similar to
those in metachromatic leukodystrophy. Nine cases with early
juvenile and juvenile onset have been reported [79].
3.12.4. Sap-C deficiency
Sap-C was first isolated from spleens of patients of Gaucher
disease [222]. It is required for the lysosomal degradation of
glucosylceramide by glucosylceramide-β-glucosidase [222]
and lends protease-resistance to the enzyme inside the cell
[223]. Recently, the solution structure of Sap-C has been solved
[224]. In contrast to the mode of action of the GM2-activator
and of Sap-B, Sap-C can activate glucosylceramide-β-glucosi-
dase directly [134,135,222]. Sap-C deficiency leads to an
unusual juvenile form of Gaucher disease and an accumulation
of glucosylceramide mainly in brain, liver and spleen [225,226].
Until now, only two human patients with point mutations in one
allele of the Sap-C domain of prosaposin have been diagnosed.
The mutations led to the substitution of the same cysteine
residue and the subsequent loss of a disulfide bridge in the
variant proteins. The clinical findings are similar to those in
Gaucher disease, type 3. Until recently, the other allele remained
unidentified in the two patients. A recent work [227]
demonstrated a Q430X mutation in the Sap-D-domain on the
other allele, so that at least one of the patients is compound
heterozygote for Sap-C- and prosaposin deficiency.
3.12.5. Sap-D
Sap-D stimulates lysosomal ceramide degradation by acid
ceramidase in in-vitro [198] and in cultured cells [199]. In Sap-
D deficient mice, ceramides, particularly those containing
hydroxy fatty acids, accumulate in the kidney and the brain of
the animals [228], which, however, suffer also from severe
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defect of this cofactor are unknown to date.
4. Pathogenesis of spingolipidoses
Sphingolipidoses display a high degree of phenotypic
variability [229]. Onset, development, and symptoms vary
widely between different sphingolipidosis, but can also differ
drastically within one and the same disease. One primary factor
that determines the pathogenesis of the diseases is the cell-type
specific pattern of glycosphingolipid expression. Lipid storage
in lipidosis patients occurs especially in those cells and organs
in which the lipid substrates of the corresponding deficient
degrading system are prevalently synthesized or taken up by
phagocytosis. Thus, complex gangliosides are predominantly
formed in neuronal cells, so that altered catabolism of these
glycolipids leads initially to damage of the central nervous
system. Ceramide is essential for skin function and contributes
to the formation of water permeability barrier. This explains the
severe skin-phenotype of patients with a complete loss of
glucosylceramide-β-glucosidase activity, which liberates extra-
cellular ceramide from a more water-soluble precursor [138].
Galactosylceramide and sulfatide are characteristic lipids of
myelin, so that in both, Krabbe's disease and metachromatic
leukodystrophy, the myelin-forming cells are primarily
affected. Alternatively, the lipid load of a cell may not be
primarily determined by endogenous synthesis of the respec-
tive lipid, rather than by uptake. Thus, in Gaucher disease,
storage is especially manifest in macrophages, which have
large amounts of sphingolipids to degrade after phagocytosis of
cells.
Besides the cell type-specific expression of sphingolipids,
the second important factor is the residual activity of the
defective enzyme in many, although not all LSDs. Onset and
severity of the storage disease is partly determined by the
residual activity of the gene product in the lysosomes [230,231].
A complete deficiency of a lysosomal enzyme leads to an early
onset and a severe course of the disease, whereas only a few
percent of residual activity can be sufficient to delay the onset of
the disease, cause an attenuated course, and lead to the often
misdiagnosed adult forms of the diseases [232]. Although this is
valid for most of the LSDs, patients with identical genotype
and, accordingly, formal similar residual activity, can undergo
different courses of a disease. Apparently, other genetic and
epigenetic factors contribute to the expression of a disease in an
individual patient.
For some LSDs, so-called enzyme pseudodeficiencies have
been described. This term refers to individuals who have a
substantial reduction of enzyme activity, but do not develop any
lysosomal accumulation. Pseudodeficiencies are due to poly-
morphisms in the genes of the respective enzymes that cause the
reduction of enzyme activity. They support the threshold theory
[230], according to which only the decrease of the variant
enzyme activity below a critical threshold leads to a reduced
turnover rate and subsequent accumulation of the substrate. The
theory is valid for most sphingolipidoses [81]. It is also the basis
for the current therapeutic approaches, since it predicts thatslight elevations of enzyme activity can drastically improve the
conditions of the patients (see Section 6).
A direct consequence of the metabolic blockage is the
accumulation of the corresponding enzyme substrates. The
majority of the amphiphilic storage compounds is not excreted
by the affected cells, although it is known that lysosomes of
some cell types can secrete their contents after fusion with the
plasma membrane [233], or undergo calcium ion-regulated
exocytosis for plasma membrane repair [234]. Extracellular
occurrence of storage material, as that of sulfatide in urine and
cerebrospinal fluid in metachromatic leukodystrophy, has been
attributed to lysosomal exocytosis [235]. The growing amount
of accumulating material might initially lead to a mechanical
damage of the cell, and subsequently to apoptosis (e. g.
[236,237]). Hypertrophy of affected organs is frequently
observed, although the storage material itself contributes only
to a small extent to mass increase. For example, an increase in
heart weight by 1000 g cannot be explained by the accumulation
of an amount of 3.5 g globotriaosylceramide as the storage
substance [238]. Therefore, hypertrophy secondary to lysoso-
mal storage is an important factor in pathogenesis.
In addition, the pathogenesis can be influenced by the nature
of the storage material. The degradation disorder can be
accompanied by formation of bioactive substances. A highly
cytotoxic substance, galactosylsphingosine (psychosine) is not
sufficiently degraded in cells of patients suffering from Krabbe
disease. It leads to the destruction of affected cells, before a
significant accumulation can occur [239]. Galactosylsphingo-
sine has been recognized as a ligand of the TDAG8-receptor
[240]. Subsequent inhibition of cytokinesis explains the
formation of multinuclear globoid cells in the brain of patients
of Krabbe disease [241]. In addition, psychosine might also act
by uncoupling mitochondrial respiratory chain [242]. Other
examples for the formation of toxic substances are glucosyl-
sphingosine in Gaucher disease [243], lysosulfatide in meta-
chromatic leukodystrophy [244], sphingosylphosphorylcholine
in Niemann–Pick-disease, type A [245], and lysoglycosphin-
golipids in the other disorders. Neuronal dysfunction might also
develop in response to morphologically active substances
[246,247] like ganglioside GM2, which is normally expressed
on neurons during neuritogenesis, with subsequent formation of
meganeurites and axonal spheroides [73].
Secondary to lipid and glycolipid storage, downstream
effects of lysosomal storage contribute to the pathogenesis of
these diseases. For example, in patients of Gaucher disease
[141], in the mouse model of Sandhoff disease [248], in animal
models of other gangliosidoses [249] and in other LSDs [73],
inflammatory responses like macrophage activation or cytokine
release have been reported. As demonstrated by deletion of the
macrophage-inflammatory protein 1α gene in the Sandhoff
disease mouse [250], inflammation is an important factor for
neuronal death, eventually also via disruption of the blood brain
barrier [73]. In addition to macrophage-inflammatory protein
1α, also rab-activation by cholesterol, which secondarily
accumulates in most sphingolipid storage diseases, might
account for this effect [251]. Other secondary effects, as on
lipid trafficking [252], phospholipid metabolism, calcium ion
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have been observed.
5. Diagnosis
The diagnosis of sphingolipidoses [256] is based on the
evaluation of clinical symptoms and characteristic pathological
manifestations, analysis of storage compounds, and especially
the measurement of enzyme activities of the individual
hydrolases. Enzyme sources are serum, leukocytes, cultured
skin fibroblasts, amnion cells, chorion villi, or biopsy material.
If enzyme activity or stability in serum are low, activity might
be determined in lymphocytes or cultured skin fibroblasts.
Disease markers like plasma chitotriosidase in Gaucher disease
[144] are valuable means for diagnosis and following
therapeutic success.
Natural or synthetic substrates with fluorogenic or chromo-
genic properties are frequently employed [256]. The analysis of
substrate accumulation can be demonstrated in cultured cells,
degradation capacity can be determined by radiolabelled
substrates or catabolic substrate precursors. For example, for
Farber disease, radiolabelled ceramide, sulfatide, or sphingo-
myelin can be used. Also altered pattern of sphingolipid
trafficking might be used for diagnostic purposes [252]. The
diagnosis of a sphingolipidoses can also be achieved by
biosynthetic labelling of the sphingolipids in cells derived from
patients and in normal cells. After a long chase period, the
substrate whose degradation is impaired will be labelled to a
greater extent than in control cells. The advantage of this
method is that proteins and lipids are tested in their natural and
topological correct environment. Furthermore, the amount of
the radioactivity incorporated into the substrate correlates
directly with the extent of the enzyme defect. In addition, this
method also allows the identification of sphingolipidoses
caused by the absence of activator proteins [199].
6. Therapeutic approaches
Many of the discussed disorders remain untreatable and
represent a high burden on the patients and their families. The
theoretical basis for the therapeutic approaches toward sphingo-
lipidoses is the “threshold theory” [230]. According to this theory,
the ratio of substrate influx into the lysosomes and the degradation
capacity determines the onset and severity of the diseases. Both
parameters can be addressed by therapeutic approaches, espe-
cially since the theory predicts that already slight changes in this
ratio can improve the condition of the patients.
The objective of most of the causal therapies of sphingoli-
pidoses is the restoration of the defective degradation capacity
within the lysosome. The current strategies for causal treatment
that are in use or under evaluation [257,258] are enzyme
replacement therapy (ERT), cell-mediated therapy (CMT)
including heterologous bone marrow transplantation (BMT)
and cell-mediated “cross correction”, gene therapy, and
enzyme-enhancement therapy with chemical chaperones
[122,257,259,260]. An additional strategy for the treatment of
sphingolipidoses consists in the reduction of substrate influxinto the lysosomes. This can be achieved by substrate reduction
(substrate deprivation) therapy [261].
6.1. Enzyme replacement therapy (ERT)
The aim of ERT [262,263] is to diminish substrate storage by
the exogenous supply of the defective lysosomal enzyme. This
was demonstrated for many LSDs in cultured cells, and in part
also in animal models, where the proteins are taken up by cells
by receptor-mediated endocytosis. The enzymes are generally
targeted for uptake by the manose-6-phosphate receptor system,
present in nearly all cells, or the mannose receptor, present in
cells of the macrophage lineage. To date, ERT of sphingolipi-
doses is successfully applied to patients suffering from type I of
Gaucher disease and Fabry disease [257]. The blood–brain
barrier prevents therapeutic enzymes from reaching neural cells
and thus limits the applicability of this therapeutic method for
treatment of central nervous system diseases.
6.2. Cell-mediated therapy (CMT)
In this case, cells are used as therapeutic agent [264] to
replace or compensate the defective cell population with normal
equivalents, so that tissue or organ function might be restored,
or to release enzymes for uptake by deficient cells (“cross
correction”). This can be achieved by bone marrow transplanta-
tion (BMT), or by the use of neural progenitor cells as examples
of this method. For example, intracerebral transplantation of
transduced neural progenitor cells into the brain of the mouse
model of Niemann–Pick disease, type A, led to a reversal of
storage [265]. Also delivery of functional proteins by axonal
transport might be further explored in the future [266].
There is currently evidence that CMT significantly alleviates
pathologic manifestations of the CNS in LSDs. There are
numerous examples for bone marrow transplantations that led to
improvement of therapeutic parameters. This is not necessarily
due to cross correction, which has been demonstrated only in
few cases, but can also be achieved by immunosuppressive
effects. BMT has been applied to human patients, e.g., of
Krabbe disease and MLD [267,268]. In animal models of LSDs
[269,270], this has led to an improvement of the neurological
symptoms and the regression of neuronal injury. More than 500
patients of lysosomal storage disorders have been treated with
allogeneic stem cell transplantation with variable success [271].
In animal models, direct implantation of cells and the use of
BMT to deliver microglial/brain macrophage precursors have
both positive effects.
6.3. Gene therapy
This approach [272] is based on the insertion of a functional
copy of the mutated gene into cells, which in turn produce the
deficient protein. The gene therapy approach takes advantage of
the process of cross correction. The deficient enzyme should be
stably over-expressed by a few cells, secreted in high levels, and
thus correct the phenotype of adjacent cells. Retro- and
lentiviral vectors are currently evaluated [273]. Especially
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this concept [274].
At the cell culture level, transduction experiments have been
carried out for example with retrovirally-mediated galactosyl-
ceramide-β-galactosidase cDNA [275]. A lentiviral vector also
corrected β-hexosaminidase deficiency in human Sandhoff
fibroblasts [276]. In the mouse model of another LSD, Sly
syndrome (mucopolysaccharidosis VII), the visceral pathology
was corrected by adenovirus-mediated gene transfer [277,278].
Recent developments include the reversal of storage in the
animal model of Tay–Sachs disease by injection of a Herpes
simplex vector encoding for the β-hexosaminidase α-subunit
into the brain of the animals [279].
Gene therapy is expected to be an effective concept for the
treatment of LSDs with CNS involvement. Several approaches
have been successfully carried out in the animal model of Tay–
Sachs and Sandhoff disease. In the murine model of Sandhoff
disease, the intracerebral injection of a recombinant adenoviral
vector encoding the β-subunit of β-hexosaminidase A resulted
in nearly normal levels of enzymatic activity in the entire brain.
The addition of hyperosmotic concentrations of mannitol
allowed an enhancement of vector diffusion [280].
In humans, the major difficulty in the employment of this gene
therapy approach for treatment of CNS diseases is to efficiently
deliver a gene therapy vector to the brain through a systemic
route. This, the limited duration of gene expression, and other
obstacles remain to be overcome before this treatment can be
successfully applied to affected humans. Another technical
problem relates to immune response in null patients leading to
only transient benefit in experimental models using some vectors.
6.4. Enzyme-enhancement therapy
This recently developed method relies on the use of chemical
chaperones [260,263]. These substances can bind to enzymes,
which are variant, but not completely defective by certain
mutations and have an intact catalytic center. Chemical
chaperones stabilize the residual functional conformation, and
prevent the premature degradation of such enzymes by the
quality control system in the ER [281]. Thereby, they enhance
the fraction of the functional variant protein and the degradation
capacity in the lysosomes. Substrate analogs and enzyme
inhibitors have been used to stabilize the variant proteins
defective for example in Fabry disease [122], Gaucher disease
[282], GM1 gangliosidosis [95], and GM2 gangliosidosis [283].
Of considerable value for this and the substrate reduction
approach are iminosugars of the nojirimycin type (Fig. 5) [284].
Members of this substance class are in clinical use as inhibitorsFig. 5. Structures of N-butyldeoxynojirimycin, N-butyldeoxygalactonojirimy-
cin, and L-cycloserine.of glycosphingolipid biosynthesis, but have also been investi-
gated as chemical chaperones of various lysosomal glycoside
hydrolases.
6.5. Substrate reduction therapy (SRT)
The pathological accumulation of a substance in the
lysosome occurs as long as biosynthesis continues. Using
inhibitors of sphingolipid biosynthesis, the influx of substrate
into the lysosomes may be reduced. The proof of principle of
the substrate reduction approach [261,285] has been demon-
strated in a genetic model: Sandhoff disease mice were
crossbred with mice defective in the biosynthetic enzyme
GM2/GD2-synthase [286]. The life span of these animals was
much longer, however, they developed a late-onset neurological
disease due to the accumulation of oligosaccharides.
Inhibitors of glycosphingolipid biosynthesis [1] are suitable
to reduce substrate influx into the lysosomes. For example, the
ceramide glucosyltransferase inhibitor N-butyldeoxynojirimy-
cin (miglustat, Zavesca®), has been initially investigated in the
animal model of Tay–Sachs disease [261]. Its efficacy could
be demonstrated in ongoing clinical trials for the treatment of
human patients of Gaucher disease, type I [287,288].
Substrate reduction with N-butyldeoxynojirimycin and bone
marrow transplantation, led to an increased survival of the
mouse model of Sandhoff disease, and also treatment with N-
butyldeoxygalactonojirimycin [289] showed promising results.
Addressing the neuroinflammatory response in Sandhoff mice
with non-steroidal anti-inflammatory drugs further increased
lifetime of the N-butyldeoxynojirimycin-treated animals [290].
Inhibition of ceramide glucosyltransferase with N-butylnojir-
imycins is suitable for substrate reduction therapy of diseases
that are caused by accumulation of substances derived from
glucosylceramide, but not for Niemann–Pick-disease A,B,
Krabbe disease, or MLD. In twitcher mice, the model for
Krabbe disease, substrate reduction with L-cycloserine (Fig. 5)
led to improved conditions and prolonged lifespan [291].
Substrate reduction therapy applied to patients with some
residual enzymatic activity or combined with methods, which
restore this activity, is expected to be helpful in the treatment of
sphingolipidoses.
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